BiotechTube
Home/BillionToOne/Oguzhan Atay, PhD
OA

Oguzhan Atay, PhD

Co-Founder, CEO, and Board Chair

BillionToOne

Therapeutic Areas

Prenatal HealthOncology

BillionToOne Pipeline

DrugIndicationPhase
UNITY Complete®Non-invasive prenatal screening for fetal aneuploidies and recessive single-gene conditionsApproved/Commercial
UNITY Fetal Antigen™ (Expanded RBC & Platelet)Prenatal screening for fetal red blood cell and platelet antigen statusApproved/Commercial
Northstar Select®Pan-cancer liquid biopsy for therapy selection (actionable variants)Approved/Commercial
Northstar Response®Pan-cancer liquid biopsy for treatment response monitoringApproved/Commercial
Northstar Select® Add-On ApplicationsUnspecified expanded liquid biopsy applicationsCommercial Launch
Phase 3 Collaboration with Johnson & JohnsonUnspecified oncology indicationPhase 3

Leadership Team at BillionToOne

DT
David Tsao, PhD
Co-Founder, CTO, and Board Member
RT
Ross Taylor, MBA
Chief Financial Officer
SR
Shan Riku, MBA
Chief Product Officer
JL
John Lister
Chief Administrative Officer
AP
Anthony Pagano
Board Member, Audit Committee Chair
View full BillionToOne profile